Drug details

Turalio (pexidartinib capsules)

type of Antineoplastic Tyrosine Kinase Inhibitors, CSF1R Inhibitors

Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• loss of appetite,
• dark urine,
• vomiting,
• fever,
• yellowing of the skin or eyes (jaundice),
• itching
• right-sided upper stomach pain,
• tiredness, and

The following drugs are related to Turalio, either as a replacement or used together:

• Alecensa (alectinib capsules)
• Alunbrig (brigatinib tablets)
• Ameluz (aminolevulinic acid hydrochloride gel)
• Arimidex (anastrozole)
• Aredia (pamidronate disodium)
• Arzerra (ofatumumab injection)
• Bavencio (avelumab injection)
• Erbitux (cetuximab)
• Cytoxan (cyclophosphamide)
• Empliciti (elotuzumab for injection)
• Farydak (panobinostat capsules)
• Gazyva (obinutuzumab injection)
• Imlygic (talimogene laherparepvec suspension for intralesional injection)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)